Deals
Tevogen Signs Letter of Intent to Evaluate HRK Healthcare Deal
The deal, which is non-binding, could help the Nasdaq-listed healthcare company build toward $100 million in combined annual revenue.
biopharma
Deals
The deal, which is non-binding, could help the Nasdaq-listed healthcare company build toward $100 million in combined annual revenue.